In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose. Due to the specific action, the natural microflora is maintained. Such prophylactic treatment of nasal colonization could counteract the spread of especially methicillin-resistant staphylococcus aureus (MRSA) in hospitals and thereby prevent infections in patients.
Every third person, according to expert estimates, carries the bacterium Staphylococcus aureus in their nose - which is not dangerous in the case of healthy individuals, however quickly becomes a problem if the carrier is admitted to a hospital. This since the pathogen can enter for example into wounds in connection with surgery and potentially cause dangerous infections.
In addition there is a large risk of spread of the pathogen as a hospital bug. Especially feared are methicillin-resistant Staphylococcus aureus isolates, abbreviated MRSA, because of their resistance to many of the commonly used antibiotics.
“A rapid detection and effective elimination of MRSA colonization in the nose prior to a hospital stay is a crucial step in combating these hospital germs", so the conviction of Prof. Dr. Karsten Becker at the University Hospital Münster. The bacteria in the nose are increasingly resistant to the currently used antibiotic mupirocin and the duration of the decolonization and follow-up control is around one week. Under such circumstances, no effective MRSA prevention is possible for patients immediately in need of surgery.
Together with the Hyglos GmbH in Bernried and with support from the BMBF, scientists at the University Hospital Münster have developed a specific active substance in recent years and studied its effect: A phage lytic enzyme that is a protein from viruses that infect bacteria, specifically attacks Staphylococcus aureus cells and dissolve them. The protein was synthetically produced and optimized as a "designer protein" with the working name HY-133.
"We do like to describe it as a MRSA-killing protein, even if it sounds somewhat sensational," explains Dr. Wolf-gang Mutter from Hyglos GmbH. In fact, all Staphylococcus aureus cells, whether resistant or not resistant, will be killed by this new active substance within a very short time. And this without the natural microflora in the nose being destroyed nor does resistance develop.
In cooperation with the microbiologist Prof. Dr. Andreas Peschel, who coordinates the DZIF research on "Healthcare-associated and antibiotic-resistant infections", the active substance will now be prepared for clinical testing. More than 1.5 million euros will be provided for HY-133 development within the DZIF:
The substance will first be manufactured under GMP guidelines (manufac-turing practice according to pharmaceutical standards) and subsequently be test-ed for preclinical toxicology. The pharmacist Prof. Dr. Gerhard Winter at the LMU Munich will develop a stable formulation, so that the substance may be conven-iently and safely administered as a gel or in any other form to the patient.
The project will be conducted in view of subsequent clinical trials, in which the rapid decolonization of Staphylococcus aureus strains will be studied in the nasal flora of volunteers. "In addition to new antibiotics and vaccines we urgently need specific agents for decolonization of problematic germs. The HY-133 protein is a highly innovative active substance for this purpose, which could lead to many simi-lar development programs", Prof. Dr. Andreas Peschel adds.
That the fight against resistant hospital germs is taken very seriously at the political level, is reflected in the coming week: At the G7 summit in Elmau the topic antibi-otic resistance is on the agenda.
In case you need any pictures, please contact:
Prof. Dr. Andreas Peschel
University of Tübingen
DZIF-Coordinator „Healthcare-associated and antibiotic-resistant infections“
T +49 7071-29-81515
Prof. Dr. Karsten Becker
University Hospital Münster
T +49(0) 251-83-55375
Prof. Dr. Gerhard Winter
Ludwig Maximilian University of Munich
T +49(0) 89-2180-77022
Dr. Wolfgang Mutter
Hyglos GmbH, Bernried am Starnberger See
Ms. Karola Neubert and Ms. Janna Schmidt
At the German Center for Infection Research (DZIF) nationwide around 300 scien-tists from 32 institutions jointly develop new approaches for prevention, diagnosis and treatment of infectious diseases. One of the focal points is the research on hospital germs and antibiotic-resistant bacteria. The DZIF is funded by the BMBF. More information on www.dzif.de
University of Tübingen – Infectious Diseases and Microbiology form a major focus of research at the University of Tübingen, especially in the Interfaculty Institute for Microbiology and Infection Medicine (IMIT). The study of staphylococci, bacte-ria that often develop resistance to antibiotics and cause infections in the hospital, is a particular focus of the IMIT researchers. www.uni-tuebingen.de
University Hospital Münster (UKM) represents cutting-edge medicine in the German hospital landscape as well as research at the highest international level. Important research priorities of the UKM Institute of Medical Microbiology are staphylococci - pathogens and infections - as well as diagnostics, typing, character-ization and susceptibility testing of microorganisms. www.klinikum.uni-muenster.de
Ludwig Maximilian University of Munich (LMU), Department of Pharmacy - The development of stable formulations for protein drugs and the administration of new biotech drugs in sustained release forms or their local application are key research areas in Pharmaceutical Technology at the LMU. Only with appropriate forms of preparation it will be possible in the end, to successfully apply sensitive substances such as the new phage lytic enzyme. www.uni-muenchen.de
Hyglos GmbH is a biotechnology company based in the Biotechnology Center Bernried south of Munich. With its proprietary technology the Hyglos scientists develop highly specific bacteriophage-based agents for the detection and elimina-tion of harmful bacteria and bacterial toxins. Hyglos is an IAFP Innovation awardee for such technological advances. www.hyglos.com
Karola Neubert | idw - Informationsdienst Wissenschaft
Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena
Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University
DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.
Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
15.12.2017 | Power and Electrical Engineering
15.12.2017 | Materials Sciences
15.12.2017 | Life Sciences